Connect Biopharma Holdings Limited reported positive topline results from the global Phase II clinical trial of CBP-201 administered subcutaneously to adult patients with moderate-to-severe atopic dermatitis.
[Connect Biopharma Holdings Limited]
Sorry, but the selected Zotpress account can't be found.
